Maiti Biplab K
National Institute of Technology Sikkim, Ravangla Campus, Barfung Block, Ravangla Sub Division, South Sikkim 737139, India.
ACS Pharmacol Transl Sci. 2020 Sep 28;3(5):1032-1034. doi: 10.1021/acsptsci.0c00136. eCollection 2020 Oct 9.
Acute respiratory distress syndrome (ARDS) is one of the critical stages of COVID-19, leading to lung injury and hemolysis. Dysfunctional hemoglobin (Hb) suffers low-level oxygenation, overloaded iron, and down-regulation of hemeoxygenase-1 (HO-1), representing potential therapeutic interventions. This Viewpoint outlines the Hb-HO-1 system as a host-cell target, and proposes possible therapies, including iron chelation and CO therapies, against COVID-19 with ARDS.
急性呼吸窘迫综合征(ARDS)是新型冠状病毒肺炎(COVID-19)的关键阶段之一,可导致肺损伤和溶血。功能失调的血红蛋白(Hb)存在低水平氧合、铁过载以及血红素加氧酶-1(HO-1)下调等情况,这些表现代表了潜在的治疗干预靶点。本观点将Hb-HO-1系统概述为宿主细胞靶点,并提出了针对伴有ARDS的COVID-19的可能治疗方法,包括铁螯合疗法和一氧化碳(CO)疗法。